Analysis of hospital admissions associated with digitalis glycosides;Fingerhut - ein alter hut? Eine analyse stationärer aufnahmen durch digitalisassoziierte unerwünschte arzneimittelwirkungen

Medizinische Klinik

Volumn 102, Issue 8, 2007, Pages 603-611

  Schmiedl, Sven ^a   Szymanski, Jacek ^a   Rottenkolber, Marietta ^b   Drewelow, Bernd ^c   Haase, Grit ^c   Hippius, Marion ^d   Reimann, Ilselore R ^d   Siegmund, Werner ^e   May, Karen ^e   Haack, Sara ^a   Hasford, Jörg ^b   Thürmann, Petra A ^a,f  

^a UNIVERSITY OF WITTEN HERDECKE   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY OF ROSTOCK   (Germany)

^d FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^e UNIVERSITY OF GREIFSWALD   (Germany)

^f HELIOS KLINIKUM WUPPERTAL   (Germany)

Author keywords

Adverse drug reaction; Digitalis glycoside; Digitoxin; Hospitalization; Overdose

Indexed keywords

ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIGITALIS; DIGITALIS GLYCOSIDE; DIGITOXIN; DIURETIC AGENT;

ADULT; ARTICLE; BODY WEIGHT; BRADYCARDIA; CONTROLLED STUDY; DATA ANALYSIS; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG OVERDOSE; DRUG SURVEILLANCE PROGRAM; FEMALE; GASTROINTESTINAL SYMPTOM; GERMANY; HEART FAILURE; HOSPITAL ADMISSION; HUMAN; INCIDENCE; MALE; PRESCRIPTION; SEX DIFFERENCE;

ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; AGED, 80 AND OVER; ARRHYTHMIAS, CARDIAC; CARDIOTONIC AGENTS; DIGITALIS GLYCOSIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG MONITORING; FEMALE; GERMANY; HEART FAILURE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PATIENT ADMISSION;

EID: 34548447222     PISSN: 07235003     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00063-007-1064-x     Document Type: Article

References (46)

1. The Digitalis in Acute Atrial Fibrillation (DAAF) Trial Group. Intravenous digoxin in acute atrial fibrillation. Results of a randomised, placebo-controlled multicentre trial in 239 patients. Eur Heart J 1997;18:649-54.
2. Withering W. An account of the foxglove and some of its medical uses. Birmingham: Publ Swinney, 1785.
3. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997;336:525-33.
4. Rathore SS, et al. Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med 2002;347:1403-11.
5. Rathore SS, et al. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA 2003;289:871-8.
6. Adams KF, et al. Relationship of serum digoxin concentration to mortality and morbidity in women in the Digitalis Investigation Group trial. J Am Coll Cardiol 2005;46:497-504.
7. Ahmed A, et al. Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary Digitalis Investigation Group trial. Circulation 2006;114:397-403.
8. Nink K, Schröder H. Arzneimittelverordnungen nach Alter und Geschlecht. In: Schwabe U, Paffrath D, Hrsg. Arzneiverordnungs-Report 2005, Berlin-Heidelberg-New York: Springer, 2006:980-92.
9. Glaeske G, Janhsen K. GEK-Arzneimittel-Report 2006. Auswertungsergebnisse der GEK-Arzneimitteldaten aus den Jahren 2004 und 2005. Sankt Augustin: Asgard, 2006:274-5.
10. Eschenhagen T. Kardiaka. In: Schwabe U, Paffrath D, Hrsg. Arzneiverordnungs-Report 2005, Berlin-Heidelberg-New York: Springer, 2006:686-90.
11. Vöhringer HF, Rietbrock N. Digitalis therapy in renal failure with special regard to digitoxin. Int J Clin Pharmacol Ther Toxicol 1981;19:175-84.
12. Kirch W, et al. Digitoxin in patients with hepatorenal insufficiency after repeated oral administration. Eur Heart J 1989;10:40-7.
13. Belz GG, Breithaupt-Grogler K, Osowski U. Treatment of congestive heart failure - current status of use of digitoxin. Eur J Clin Invest 2001;31:Suppl 2:10-7.
14. Thürmann PA, Schmitt K. Detection and evaluation of adverse drug reactions. Med Klin 2000;95:Spec No 1:4-8.
15. Göttler M, Schneeweiss S, Hasford J. Adverse drug reaction monitoring - cost and benefit considerations part II: Cost and preventability of adverse drug reactions leading to hospital admission. Pharmacoepidemiol Drug Saf 1997;6:Suppl 3:79-90.
16. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998;279:1200-5.
17. Mühlberger N, Schneeweiss S, Hasford J. Adverse drug reaction monitoring - cost and benefit considerations part I: Frequency of adverse drug reactions causing hospital admission. Pharmacoepidemiol Drug Saf 1997;6:Suppl 3:71-7.
18. Schneeweiss S, et al. Admissions caused by adverse drug events to internal medicine and emergency departments in hospitals: a longitudinal population-based study. Eur J Clin Pharmacol 2002;58:285-91.
19. Hippius M, et al. Adverse drug reaction monitoring - digitoxin overdosage in the elderly. Int J Clin Pharmacol Ther 2001;39:336-43.
20. Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting adverse drug reactions. Am J Hosp Pharm 1992;49:2229-32.
21. Bégaud B, et al. Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France. Therapie 1985;40:115-8.
22. Drugdex, Micromedex® Healthcare Series., Greenwood Village: Thomson Micromedex, 2006.
23. Aronson JK, ed. Meyler's side effects of drugs. The international encyclopedia of adverse drug reactions and interactions, 15th edn. Amsterdam: Elsevier, 2006.
24. Hoppe UC, Erdmann E. Leitlinien zur Therapie der chronischen Herzinsuffizienz. Im Auftrag der deutschen Gesellschaft für Kardiologie. Z Kardiol 1998;87:645-61.
25. Fachinformation Digimerck® . Frankfurt/Main: Rote Liste Service GmbH, Stand: August 2006.)
26. Moore N, et al. Frequency and cost of serious adverse drug reactions in a department of general medicine. Br J Clin Pharmacol 1998;45:301-8.
27. Hallas J, et al. Drug related admissions to medical wards: a population based survey. Br J Clin Pharmacol 1992;33:61-8.
28. Pedone C, et al. Comparison of digitalis-related adverse events in hospitalized men and women in Italy: an observational study. Clin Ther 2005;27:1922-9.
29. Roever C, et al. Comparing the toxicity of digoxin and digitoxin in a geriatric population: should an old drug be rediscovered? South Med J 2000;93:199-202.
30. Warren JL, et al. Hospitalizations with adverse events caused by digitalis therapy among elderly Medicare beneficiaries. Arch Intern Med 1994;154:1482-7.
31. Kernan WN, et al. Incidence of hopsitalization for digitalis toxicity among elderly Americans. Am J Med 1994;96:426-31.
32. Keller E. Unerwünschte Arzneimittelwirkungen: Ansätze zur Inzidenzschätzung und Signalgenerierung mit fallbasierten Pharmakovigilanzdaten. Dissertationsschrift, Medizinische Fakultät, LMU München, 2005 (Epub: http://edoc.ub.uni-muenchen.de/archive/00005207/01/ Keller_Elena.pdf).
33. Laroche ML, et al. Is inappropriate medication use a major cause of adverse drug reactions in the elderly? Br J Clin Pharmacol 2007;63:177-86.
34. Kannel WB, Cupples A. Epidemiology and risk profile of cardiac failure. Cardiovasc Drugs Ther 1998;2:Suppl 1:387-95.
35. Kannel WB, et al. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 1998;82:2N-9N.
36. Miura T, et al. Effect of aging on the incidence of digoxin toxicity. Ann Pharmacother 2000;34:427-32.
37. Erdmann, E. Besonderheiten der Herzglykosidtherapie im Alter. Internist (Berl) 1991;32:472-8.
38. Bohmer T, Roseth A. Prolonged digitoxin half-life in very elderly patients. Age Ageing 1998;27:222-4.
39. Hardman JG, Gilman AG, Limbird LE, eds. Goodman and Gilman's the pharmacological basis of therapeutics, 9th edn. New York: McGraw-Hill, 1996.
40. Eberhart DC, et al. Species differences in the toxicity and cytochrome P450 IIIA-dependent metabolism of digitoxin. Mol Pharmacol 1991;40:859-67.
41. Pauli-Magnus C, et al. P-glycoprotein-mediated transport of digitoxin, alpha-methyldigoxin and beta-acetyldigoxin. Naunyn Schmiedebergs Arch Pharmacol 2001;363:337-43.
42. Consensus recommendations for the management of chronic heart failure. On behalf of the membership of the advisory council to improve outcomes nationwide in heart failure. Am J Cardiol 1999;83(2A):1A-38A.
43. Levy EG. Thyroid disease in the elderly. Med Clin North Am 1991;75:151-67.
44. Kjeldsen K, et al. Effect of thyroid function on number of Na-K pumps in human skeletal muscle. Lancet 1984;2:8-10.
45. Erdmann E. Changes of affinity and capacity of cardiac glycoside receptors. Arzneimittelforschung 1985;35:1948-52.
46. Blaustein MP, et al. Sex, digitalis, and the sodium pump. Mol Interv 2003;3:68-72.